There are currently 1994 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes
NCT05208164
Recruiting
The proposed research and training will allow Dr. Alana Biggers to obtain critical research skills and study a mindfulness meditation program designed to improve sleep and reduce stress in African-American adults with diabetes. If effective, this program may reduce the risk of cardiovascular disease among African-Americans with type 2 diabetes who are at high risk of cardiovascular disease.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
03/04/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Type 2 Diabetes, Sleep, Stress
Register for Updates
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
NCT04747912
Recruiting
This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this study hope to learn if adding InO to standard induction treatment for Ph+ ALL will lead to quicker, complete molecular remission (where the disease is not detectable even with very sensitive testing techniques). The purpose of this research is to gather... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
Register for Updates
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
NCT06052072
Recruiting
This early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
03/03/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Group 2 Pulmonary Hypertension, Heart Failure
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Chicago, Illinois
Conditions: Neoplasms
Register for Updates
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients with Vitiligo
NCT06109649
Recruiting
The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/28/2025
Locations: CLINUVEL site, Chicago, Illinois
Conditions: Vitiligo
Register for Updates
Mapping Corticoreticulospinal Motor Control in Chronic Hemiparetic Stroke
NCT06598150
Recruiting
This study uses functional magnetic resonance imaging to map neural activity throughout the central nervous system during a shoulder abduction task to characterize what motor pathways are being used post-stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Stroke, Hemiparesis
Register for Updates
Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)
NCT04827420
Recruiting
The over-arching research question is: Does message (Advise) and referral approach (Refer) influence a patient's willingness to "opt-in" to receive a call from an Illinois Tobacco Quitline (ITQL) smoking cessation coach in patients at MSHC. Primary UH3 study aim: Compare the effect of the portal-delivered Choice message (Arm 1) to the Information-only message (Arm 3) on linkage to the Illinois Tobacco Quitline (i.e., spoke to a Quitline coach). Secondary UH3 aims are to: Examine the reach of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Tobacco Use Cessation
Register for Updates
Longitudinal Study of the Porphyrias
NCT01561157
Recruiting
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Gender:
ALL
Ages:
1 minute and above
Trial Updated:
02/28/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Acute Porphyrias, Cutaneous Porphyrias
Register for Updates
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Recruiting
This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
02/27/2025
Locations: John H Stroger Jr Hospital of Cook County, Chicago, Illinois
Conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Rush University, Chicago, Illinois
Conditions: Leukemia, Myeloid, Acute
Register for Updates
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Asthma Allergy Center of Chicago, Chicago, Illinois
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
NCT05494593
Recruiting
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome. In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR. Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic... Read More
Gender:
MALE
Ages:
6 years and below
Trial Updated:
02/27/2025
Locations: Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois
Conditions: Mucopolysaccharidosis (MPS), Hunter Syndrome
Register for Updates